Feature | CD8i N (%) | CD8s N (%) | ||||||
---|---|---|---|---|---|---|---|---|
N (%) | Low | High | P-value | Low | High | P-value | ||
Age (years) (n = 130) | Median (min, max) | 72 (30-91) | 71.4 (30-91) | 73.8 (50-90) | 0.3872 | 72.4 (30-91) | 71 (30-90) | 0.876 |
Gender (n = 130) | Male | 80 (61.5) | 61 (61.0) | 19 (63.3) | 1.0 | 40 (61.5) | 40 (61.5) | 1.0 |
Female | 50 (38.5) | 39 (39.0) | 11 (36.7) | 25 (38.5) | 25 (38.5) | |||
Histological subtype (n = 130) | Non-mucinous | 106 (81.5) | 80 (80.0) | 26 (86.7) | 0.5923 | 49 (75.4) | 57 (87.7) | 0.1123 |
Mucinous | 24 (18.5) | 20 (20.0) | 4 (13.3) | 16 (24.6) | 8 (12.3) | |||
Tumour location (n = 129) | Left | 43 (33.3) | 33 (33.3) | 10 (33.3) | 0.8606 | 21 (32.3) | 22 (34.4) | 0.7333 |
Rectum | 30 (23.3) | 22 (22.2) | 8 (26.7) | 17 (26.2) | 13 (20.3) | |||
Right | 56 (43.4) | 44 (44.4) | 12 (40.0) | 27 (41.5) | 29 (45.3) | |||
pT (n = 130) | pT1 + pT2 | 30 (23.1) | 15 (15.0) | 15 (50.0) | <0.0001 | 12 (18.5) | 18 (27.7) | 0.2979 |
pT3 + pT4 | 100 (76.9) | 85 (85.0) | 15 (50.0) | 53 (81.5) | 47 (72.3) | |||
pN (n = 130) | pN0 | 54 (41.5) | 34 (34.0) | 20 (66.7) | 0.0015 | 26 (40.0) | 28 (43.1) | 0.8588 |
pN1-2 | 76 (58.5) | 66 (66.0) | 10 (33.3) | 39 (60.0) | 37 (56.9) | |||
cT (n = 30) | cT1-2 | 9 (31.0) | 6 (27.3) | 3 (42.9) | 0.6424 | 5 (45.5) | 4 (22.2) | 0.2371 |
cT3-4 | 20 (69.0) | 16 (72.7) | 4 (57.1) | 6 (54.6) | 14 (77.8) | |||
cN (n = 113) | cN0 | 68 (62.4) | 50 (59.5) | 18 (72.0) | 0.2583 | 32 (57.1) | 36 (67.9) | 0.3229 |
cN1-2 | 41 (37.6) | 34 (40.5) | 7 (28.0) | 24 (42.9) | 17 (32.1) | |||
No. LN collected (n = 130) | Median (min, max) | 22 (4-73) | 23.0 (6-67) | 16.5 (4-73) | 0.0842 | 23.0 (4-67) | 18 (6-73) | 0.1369 |
Tumour deposits (n = 108) | 0 | 91 (84.3) | 67 (79.8) | 24 (100.0) | 0.0117 | 42 (82.4) | 49 (86.0) | 0.792 |
≥1 | 17 (15.7) | 17 (20.2) | 0 (0.0) | 9 (17.7) | 8 (14.0) | |||
Metastasis (n = 123) | cM0 | 86 (69.9) | 63 (67.0) | 23 (79.3) | 0.2519 | 42 (68.8) | 44 (71.0) | 0.8457 |
cM1 | 37 (30.1) | 31 (33.0) | 6 (20.7) | 19 (31.2) | 18 (29.0) | |||
Lymphatic invasion (n = 113) | L0 | 29 (25.7) | 17 (19.3) | 12 (48.0) | 0.008 | 10 (18.5) | 19 (32.2) | 0.1312 |
L1 | 84 (74.3) | 71 (80.7) | 13 (53.0) | 44 (81.5) | 40 (67.8) | |||
Venous invasion (n = 114) | V0 | 57 (50.0) | 39 (44.3) | 18 (69.2) | 0.0433 | 26 (47.3) | 31 (52.5) | 0.708 |
V1-2 | 57 (50.0) | 49 (55.7) | 8 (30.8) | 29 (52.7) | 28 (47.5) | |||
Perineural invasion (n = 111) | Pn0 | 100 (90.1) | 75 (87.2) | 25 (100.0) | 0.0671 | 48 (90.6) | 52 (89.7) | 1.0 |
Pn1 | 11 (9.1) | 11 (12.8) | 0 (0.0) | 5 (9.4) | 6 (10.3) | |||
Tumour grade (n = 130) | G1-2 | 85 (65.4) | 66 (66.0) | 19 (63.3) | 0.8286 | 40 (61.5) | 45 (69.2) | 0.3566 |
G3 | 45 (34.6) | 34 (34.0) | 11 (36.7) | 25 (38.5) | 20 (30.8) | |||
Postoperative therapy (n = 127) | None | 88 (69.3) | 65 (66.3) | 23 (79.3) | 0.2524 | 41 (64.1) | 47 (74.6) | 0.2491 |
Yes | 39 (30.7) | 33 (33.7) | 6 (20.7) | 23 (36.0) | 16 (25.4) | |||
MMR status (n = 117) | Proficient | 99 (84.6) | 77 (85.6) | 22 (81.5) | 0.5596 | 52 (89.7) | 47 (79.7) | 0.1996 |
Deficient | 18 (15.4) | 13 (14.4) | 5 (18.5) | 6 (10.3) | 12 (20.3) | |||
Survival time (n = 76) | Median (95% CI) months | 73.5 (29-105) | 53.1 (22.6-73.9) | Not reached | 0.0026 | 26.4 (13.7-73.5) | 105.4 (54.9-NE) | 0.0053 |